1. Pink Sheet
  2. >>Pathways & Standards

Real-World Evidence: Observational Studies Deserve More Respect In US FDA Framework

 
• By Sue Sutter

Biopharma industry urges agency to open the door wider to use of non-randomized observational studies to support efficacy claims, but insurer Kaiser Permanente calls such studies problematic.

High resolution green, fresh and natural 3d conceptual grass over a blue sky background, a opened door at horizon ideal for religion,home,recreation,faith,business,success,oportunity or future
Industry wants an open door for use of observational studies to support efficacy claims. • Source: Shutterstock

The US Food and Drug Administration should take a more welcoming view on the use of observational studies to support new efficacy claims for approved drugs, the pharmaceutical industry believes.

Concerns about bias and the lack of randomization in observational studies need not derail the use of such real-world evidence...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards

Early Support For EMA’s Trial Of US-Style Standards In Non-Clinical Reviews

 
• By Vibha Sharma

An ongoing proof-of-concept study by the European Medicines Agency testing the use of US-style standards for submitting non-clinical raw data in marketing applications has received positive feedback from both industry and regulatory assessors so far.

New EU Approvals

 
• By Neena Brizmohun

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Tepezza, Amgen's treatment for moderate to severe thyroid eye disease.

America Next: Most Novel Agents With July Goal Dates Have Been Approved Overseas

 
• By Bridget Silverman

The US FDA will not be in its usual position as the first regulator to approve novel drugs, with only one of the six novel candidates on the July user fee calendar seeking its first approval worldwide in the US